ARVs

3.

Global Fund to benefit from “breakthrough” ARV pricing agreement

3 Oct 2017
State-of-the-art fixed dose combination regimen will cost $75 per patient per year

In what has been hailed as a “breakthrough” and a “game changer,” a pricing agreement between the Bill and Melinda Gates Foundation and two generic drug companies will result in significant savings in the cost of antiretrovirals (ARVs). As a result of the agreement, starting in 2018 a state-of-the-art fixed dose combination ARV regimen will be available in 92 developing nations at a maximum cost of $75 per patient per year.

3.

OIG audit of two Global Fund grants to Guinea finds significant weaknesses in supply chain management

5 Sep 2017
Improvements also required in grant implementation
Nevertheless, Guinea has made significant progress in the fight against the diseases

Although Guinea has made significant progress in the fight against the three diseases, despite a challenging operating environment, there are significant weaknesses in supply chain management and there are areas related to managing grant implementation that require improvement. These were the findings of an audit of Global Fund grants to Guinea conducted by the Office of the Inspector General (OIG).

8.

In brief: Important HIV-related developments

8 Aug 2017

Several important HIV-related announcements were made in the last few weeks. We provide short summaries.

“The scales have tipped”

6.

Programs supported by the Global Fund continue to show impressive results

8 Aug 2017
Gains reflect increased uptake and better reporting

The Global Fund continues to show impressive gains with respect to the number of people receiving key HIV, TB and malaria services as a result of programs supported by the Fund. Some of the gains reflect increased uptake of services, while other gains are the result of better reporting.

5.

New ARV database being piloted in the EECA region

18 Apr 2017
Provides information on drug prices and purchases

A new database is being developed in Eastern Europe and Central Asia (EECA) containing information on antiretrovirals (ARVs) in use in 15 countries: Armenia, Azerbaijan, Belarus, Estonia, Georgia, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Moldova, Poland, the Russian Federation, Tajikistan, Ukraine and Uzbekistan.

3.

Global Fund pushes back on claims of overdependence on select suppliers of ARVs

17 Apr 2017
Buyers had been warned to diversify the manufacturing base or risk supply interruptions

The Global Fund, one of the main purchasers of generic antiretroviral (ARV) medicines for HIV patients in low- and middle-income countries, has dismissed concerns that the limited number of manufacturers tapped to supply these drugs could result in immediate or future shortages. Fund officials said systems are in place to forecast demand, deal with any supply disruptions and increase production to meet future need.

5.

Negotiations to assist Venezuelan NGOs to address humanitarian crisis slow down

13 Mar 2017
There have been no public announcements by any of the parties

More than a month has passed since the exchange of letters between the Global Fund and the Venezuelan Network of Positive People (RVG+ in its Spanish acronym) concerning what Venezuelan civil society describe as “a humanitarian crisis.” Very little has happened in the interim, at least not that we can report publicly.

7.

L’AHF et des chercheurs appellent à plus de transparence dans les estimations de l'ONUSIDA relatives au nombre de personnes sous ARV

11 Oct 2016
Certains résultats du ‘Global Burden of Disease Study 2015’ diffèrent des estimations de l'ONUSIDA
L’ONUSIDA répond qu'il est confiant que ses données sont justes
4.

AHF and researchers call for more transparency in UNAIDS’ estimates of the numbers of people on ARVs

17 Sep 2016
The Global Burden of Disease 2015 Study produced some results that differ from the UNAIDS’ figures
UNAIDS responds that it is confident its estimates are accurate

The AIDS Healthcare Foundation (AHF), a Los Angeles-based AIDS service and activist organization with a global reach, has called for more transparency and accountability in the way UNAIDS estimates the number of people living with HIV/AIDS who are on life-saving antiretroviral treatment.

9.

More information on August funding approvals

16 Sep 2016
Details on GAC comments on grants to six countries

As reported in GFO #295, in August the Board approved $180 million in funding for 14 grants from 11 countries. The Board was acting on recommendations of the Technical Review Panel (TRP) and the Grants Approvals Committee (GAC). This article provides a summary of the some of the comments made by the GAC in its report to the Board.

Pages

Subscribe to ARVs